Zobrazeno 1 - 10
of 3 682
pro vyhledávání: '"Richard A Warren"'
Publikováno v:
Aesthetic Surgery Journal Open Forum, Vol 5 (2022)
Externí odkaz:
https://doaj.org/article/0ab2deaa9f10417c8fca45f895a66b64
Autor:
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Vanessa Taieb, Jason Eells, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1413-1423 (2024)
Abstract Introduction A matching-adjusted indirect comparison (MAIC) was conducted to assess the relative efficacy at 52 weeks (Wk52) of bimekizumab 160 mg every 4 weeks (Q4W) and ustekinumab 45 or 90 mg every 12 weeks (Q12W) in patients with psoriat
Externí odkaz:
https://doaj.org/article/4262254099cb40d39645fcfe05396997
Autor:
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1403-1412 (2024)
Abstract Introduction The relative efficacy of bimekizumab and risankizumab in patients with PsA who were biologic disease-modifying anti-rheumatic drug naïve (bDMARD naïve) or with previous inadequate response or intolerance to tumor necrosis fact
Externí odkaz:
https://doaj.org/article/ce35de981e1147979941d6203e2e5191
Autor:
Luis Puig, Antonio Costanzo, Elke M. G. J. de Jong, Tiago Torres, Richard B. Warren, Robert Wapenaar, Sven Wegner, Patricia Gorecki, Talia Gramiccia, Maria Jazra, Jozefien Buyze, Curdin Conrad
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2539-2558 (2024)
Abstract Introduction The interleukin-23p19 subunit inhibitor, guselkumab, has demonstrated improvements in clinical and patient-reported outcome (PRO) measures in patients with moderate-to-severe psoriasis. Understanding the relationship among clini
Externí odkaz:
https://doaj.org/article/ab526a4a99574512a77a238ef4a81a03
Autor:
Bernhard Korge, Olivier Vanhooteghem, Charles W. Lynde, Alena Machovcova, Marc Perrussel, Elisavet Lazaridou, Claudio Marasca, David Vidal Sarro, Ines Duenas Pousa, Frederik Fierens, Paulette Williams, Saori Shimizu, Tanja Heidbrede, Richard B. Warren
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 8, Pp 2077-2092 (2024)
Abstract Introduction Certolizumab pegol (CZP) is an anti-tumor necrosis factor alpha (TNFα) approved for the treatment of moderate to severe plaque psoriasis (PSO). However, data on its real-world use is currently limited. The objective of this stu
Externí odkaz:
https://doaj.org/article/9b8405ecefbc478e911d59e7b2e3c3c1
Autor:
Duggan, Anne
Publikováno v:
The Oxford Companion to Fairy Tales, 2 ed., 2015.
Autor:
Carr, Russell B.
Publikováno v:
Psychiatry: Interpersonal & Biological Processes. Spring2013, Vol. 76 Issue 1, p90-93. 4p.
Autor:
Birch, Dinah, Hooper, Katy
Publikováno v:
The Concise Oxford Companion to English Literature, 4 ed., 2013.
Autor:
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 817-828 (2024)
Abstract Introduction Matching-adjusted indirect comparisons (MAICs) were used to compare the efficacy of bimekizumab and secukinumab 150 mg and 300 mg at 52 weeks for the treatment of psoriatic arthritis (PsA) in patients who were biologic disease-m
Externí odkaz:
https://doaj.org/article/f5c52a1be9d64789923ca497a0e9b3a0
Autor:
Richard B. Warren, Iain B. McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Philip J. Mease
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 829-839 (2024)
Abstract Introduction Matching-adjusted indirect comparisons (MAIC) were used to assess the relative efficacy of bimekizumab 160 mg every 4 weeks (Q4W) compared to guselkumab 100 mg Q4W or every 8 weeks (Q8W) at 48/52 weeks in patients with psoriatic
Externí odkaz:
https://doaj.org/article/160b6ba0575d44a484ca18255390de4e